Financial Performance - The company recorded a total revenue of RMB 2,634.91 million for the year ended December 31, 2023, representing an increase of RMB 531.47 million or 25.27% compared to the previous year[2]. - Net profit attributable to shareholders was approximately RMB 416.12 million, reflecting a growth of 130.58% compared to the previous year, while the net profit excluding non-recurring items was RMB 383.41 million, up 141.52%[2]. - The gross profit for the year was RMB 1,853.51 million, compared to RMB 1,446.92 million in 2022, indicating a significant increase in profitability[3]. - The company reported a total comprehensive income of RMB 404.44 million for the year, significantly higher than RMB 100.70 million in 2022[4]. - The basic and diluted earnings per share for the year were RMB 2.44, compared to RMB 1.04 in the previous year, showcasing strong earnings growth[4]. - The total tax expense for the year 2023 amounted to RMB 95,991,000, an increase of 111.1% compared to RMB 45,395,000 in 2022[30]. Research and Development - Research and development expenses amounted to approximately RMB 220.10 million, an increase of RMB 37.91 million or 20.81% year-over-year, accounting for 8.35% of total revenue[2]. - The company is focusing on expanding its ophthalmic and aesthetic innovation product lines, with several key R&D projects progressing smoothly[48]. - The hydrophobic injection aspheric intraocular lens product has been approved for registration and market launch in June 2023, while other products are in various stages of clinical trials and registration[48]. - The company has initiated clinical trials for the innovative hydrophobic molded aspheric trifocal artificial lens in July 2023[56]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 1.00 per share for the year ended December 31, 2023, compared to RMB 0.40 per share in 2022, and recommended a bonus issue of 4 new shares for every 10 existing shares[2]. - The total number of H-shares repurchased in 2023 was 3,872,400, with a total expenditure of HKD 166,589,234.00[89]. - The total number of A-shares repurchased in 2023 was 1,089,486, with a total expenditure of RMB 117,145,262.95[90]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 6,389.55 million, slightly up from RMB 6,381.12 million in the previous year[5]. - Current assets increased to RMB 3,750.14 million from RMB 3,532.12 million, indicating improved liquidity[5]. - The company’s total liabilities amounted to RMB 407.95 million as of December 31, 2023, compared to RMB 118.26 million in 2022[40]. - The current portion of total liabilities was RMB 216.63 million, while the non-current portion was RMB 191.32 million[40]. Revenue Breakdown - Revenue from mainland China was RMB 2,181,814 thousand, up 28.5% from RMB 1,699,078 thousand in 2022[22]. - The ophthalmology product line generated RMB 924.65 million in revenue, accounting for 35.10% of total revenue, with a year-on-year growth of 20.72%[47]. - The medical beauty and wound care product line reported revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a significant year-on-year growth of 41.44%[47]. - The orthopedic product line's revenue reached RMB 474.26 million, making up 18.00% of total revenue, with a year-on-year increase of 22.71%[47]. Market Position and Strategy - The company has been recognized as a high-tech enterprise, allowing a preferential tax rate of 15% for certain subsidiaries in 2023[6]. - The company aims to accelerate the localization of the ophthalmic industry in China and become a globally recognized comprehensive ophthalmic product manufacturer[50]. - The company has established exclusive distribution rights for high-end corneal reshaping lenses in mainland China, enhancing its market share and influence[56]. - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, while enhancing research and development capabilities[69]. Compliance and Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[93]. - The audit committee reviewed the audited consolidated financial statements and annual results for the year ending December 31, 2023[94]. - The annual report containing all data required by the Hong Kong Listing Rules will be sent to shareholders and published on the relevant websites in due course[95].
昊海生物科技(06826) - 2023 - 年度业绩